{"id":"d326","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, D326 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"D326 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:24.358Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05698043","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-07-17","conditions":"Hypertension and Dyslipidemia","enrollment":63},{"nctId":"NCT05552495","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-09-23","conditions":"Hypertension and Dyslipidemia","enrollment":31},{"nctId":"NCT05245084","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-03-15","conditions":"Hypertension and Dyslipidemia","enrollment":64},{"nctId":"NCT04987970","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-09-12","conditions":"Hypertension and Dyslipidemia","enrollment":60},{"nctId":"NCT04312698","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-386","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-08-29","conditions":"Dyslipidemia Patients With Hypertension","enrollment":100},{"nctId":"NCT04694989","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-02-20","conditions":"Hypertension and Dyslipidemia","enrollment":62},{"nctId":"NCT04673864","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-01-17","conditions":"Hypertension and Dyslipidemia","enrollment":66},{"nctId":"NCT04388215","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-10-23","conditions":"Hypertension, Dyslipidemias","enrollment":120},{"nctId":"NCT04272502","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-06-04","conditions":"Healthy","enrollment":15},{"nctId":"NCT04223895","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-02-01","conditions":"Type2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT03920579","phase":"PHASE1","title":"A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-04-01","conditions":"Hypertension, Dyslipidemias","enrollment":30},{"nctId":"NCT03726866","phase":"PHASE1","title":"A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-31","conditions":"Dyslipidemias, Hypertension","enrollment":30},{"nctId":"NCT03609606","phase":"PHASE1","title":"A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-09","conditions":"Dyslipidemias, Hypertension","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":72,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D326","genericName":"D326","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D326 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}